GSK negotiating $1 billion sale of thrombosis drugs to Aspen
Reuters - Tue, 18 Jun, 2013LONDON (Reuters) - GlaxoSmithKline is discussing the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could be worth some ... More »GSK negotiating $1 billion sale of thrombosis drugs to Aspen
